



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

*[Handwritten signature]*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/054,429	01/22/2002	Ekambar R. Kandimalla	47508-580 (HYZ-027CIP)	7279
23483	7590	08/24/2005	EXAMINER	
WILMER CUTLER PICKERING HALE AND DORR LLP 60 STATE STREET BOSTON, MA 02109				EPPS FORD, JANET L
ART UNIT		PAPER NUMBER		
1633				

DATE MAILED: 08/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/054,429	KANDIMALLA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Janet L. Epps-Ford, Ph.D.	1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 22 June 2005.  
 2a) This action is **FINAL**.                            2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 1-3 and 5-20 is/are pending in the application.  
 4a) Of the above claim(s) 6,7,14 and 15 is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-3,5,8-13 and 16-20 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on 1/22/02 is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

## **DETAILED ACTION**

1. Claims 1-3, 5-20 are pending. Claims 6-7, and 14-15 are withdrawn.

### *Response to Arguments*

2. Applicant's arguments filed 6-22-05 with respect to claims 18-19 have been considered but are moot in view of the new ground(s) of rejection.

3. The rejection of claims 1-3, 5, 8-13, 17, and 20 under 35 U.S.C. 103(a) as being unpatentable over Gryaznov et.al. (US Patent No. 5,571,903) in view of Agrawal et al. (US Patent No. 5,691,316), is withdrawn in response to Applicant's arguments filed 6-22-05 since it is clear that Agrawal et al. does not teach the terminal covalent attachment of cyclodextrin to oligonucleotides. However, a new grounds of rejection under 35 USC 103(a) is set forth below in response to Applicant's amendment of 6-22-05.

4. The rejection of claims 16-19 under 35 USC 112, 1<sup>st</sup> paragraph in response to Applicant's arguments of 6-22-05 since it is clear that the compositions of the present invention need only one enabled use to satisfy the requirements of this statute. The pharmaceutical compositions of instant claims can be used in a cell for diagnostic purposes, for example.

### *Double Patenting*

5. Claims 18-19 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 6,372,427 in view of Papahadjopoulos et al. (US Patent No. 4,235,871; US-'871). An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g.,

*In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claim(s) 18-19 of the instant application differ from the compositions recited in claims 1-22 of the issued Patent by the presence of a pharmaceutically acceptable carrier.

6. US-‘871 disclose the preparation of nucleic acid liposomal formulations (col. 6, lines 31-43). The formulations of US-‘871 are disclosed as having the ability to enhance the bioavailability of biologically active material, introducing genetic information into cells *in vitro* and *in vivo*, introduction of recombinant DNA segments into microbial cells, or for use in diagnostic reagents for clinical tests, see col. 3, lines 28-43.

7. It would have been obvious to the ordinary skilled artisan, at the time of the instant invention, to modify the issued claims drawn to a composition comprising cooperative oligonucleotides with a pharmaceutically acceptable carrier. One of ordinary skill in the art would have been motivated to make this modification because issued claims 11-12 are drawn to the use of the claimed compositions in an *in vitro* method for inhibiting the expression of a nucleic acid, and the prior art teaches that the presence of the carrier enhances the bioavailability of biologically active material, and aids in the delivery of nucleic acid into cells *in vitro*.

#### ***Claim Rejections - 35 USC § 103***

8. Claims 1-3, 5, 8-13, 16-17 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gryaznov et al. (US Patent No. 5,571,903) in view of Weber et al. (1992).

9. Gryaznov et al. disclose compositions comprising a from two to five components comprising oligonucleotide moieties (of 4 to 12 monomers in length) that specifically anneal to a

target polynucleotide in a contiguous end-to-end fashion, wherein each oligonucleotide are modified to comprise a terminal binding moiety (col. 3, lines 1-30). As per col. 3, lines 10-20, it appears that the terminal binding moieties are covalently attached to the oligonucleotide by a number of different chemistries (see col. 6, lines 31-50). According to Gryaznov et al. the terminal binding moieties of the invention are brought into juxtaposition so that they from a stable covalent linkage or non-covalent complex. The terminal binding moieties of Gryaznov et al. confer an increase by at least fifty percent over the melting temperatures of the oligonucleotide moieties alone (col. 4, lines 10-15). The terminal binding pairs must also react specifically with each other (col. 6, lines 51-54). The oligonucleotides of Gryaznov et al. may also comprise encompass modified oligonucleotides that comprise internucleoside linkages that confer nuclease resistance, e.g. phosphorothioate, phosphorodithioate, phosphoramidate, or the like (see col. 5, lines 44-48).

However, Gryaznov et al. does not teach oligonucleotide moieties modified with streptavidin and biotin. Weber et al. describes the high affinity binding of streptavidin to biotin.

It would have been obvious to the ordinary skilled artisan at the time of the instant invention to modify the teachings of Gryaznov et al. with the teachings of Weber et al. in the design of the instant invention. One of ordinary skill in the art would have been motivated to make this modification because Weber et al. clear teach the high affinity, and specificity of streptavidin binding to biotin. The binding pairs of Gryaznov et al. are disclosed as forming stable and specific complexes, and the streptavidin and biotin binding pairs are disclosed as having those characteristics (see page 3197, Introduction, of Weber et al.) It would have been obvious at the time of the instant invention to substitute one functionally equivalent binding pair

for another with the expectation that the prior art binding pair would function in the same manner as those disclosed in Gryaznov et al.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford, Ph.D. whose telephone number is 571-272-0757. The examiner can normally be reached on Monday-Saturday, Flex Schedule.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Nguyen can be reached on (571)272-0731. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

  
Janet L. Epps-Ford, Ph.D.  
Patent Examiner  
Art Unit 1633

JLE